Appointment dossier — Small Cell Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Small Cell Carcinoma
- Cisplatin — Review evidence · 1 positive / 1 negative-mixed · PMID 30397561, 18408396
- Etoposide — Review evidence · 1 positive / 2 negative-mixed · PMID 30397561, 40129783, 37485216, 18408396
- Pembrolizumab — Review evidence · 1 positive · PMID 33163917
- Carboplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
- Durvalumab — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
- Nivolumab †Rx — Review evidence · 0 positive / 1 negative-mixed · PMID 37928288
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07610798 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations (China)
- NCT07070232 · Phase 1 / Phase 2 — A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (United States)
- NCT07751042 · Phase 1 / Phase 2 — Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab (United States)
- NCT06926075 · Phase 1 / Phase 2 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours (Australia)
- NCT04897321 · Phase 1 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (United States)
- NCT03778814 · Phase 1 — TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors (China)
- NCT05085028 · Phase 3 — A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (United Kingdom)
- NCT07502300 · Phase 3 — A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) (China)
- NCT03851445 · Phase 2 / Phase 3 — Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer (United States)
- NCT06320067 · Phase 3 — A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (United Kingdom)
- NCT07241416 · Phase 3 — A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (China)
- NCT06424067 · Phase 2 — Phase 2 Study of Fingolimod in Lung Cancers (United States)
- NCT07535437 · Phase 1 / Phase 2 — A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer (United States)
- NCT07583511 · Phase 2 — Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study (China)
- NCT04253964 · Phase 2 — Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy (United States)
- NCT07292168 · Phase 1 / Phase 2 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 (Russia)
- NCT07231068 · Phase 1 / Phase 2 — A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation (China)
- NCT07622186 · Phase 2 — A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (China)
Most-relevant first: trials that name Small Cell Carcinoma, then broader trials you may still qualify for. 1531 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07610798), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?